Objective To compare the safety and efficacy of argatroban and plasmin in the treatment of patients with acute ischemic stroke (AIS). Methods A total of 168 patients with AIS who were not eligible for intravenous thrombolysis within 48 hours of onset were randomly divided into argatroban group and plasmin group. The former was given intravenous infusion of Argatroban injection for 7 days on the basis of conventional antiplatelet therapy; the latter was given intravenous infusion of plasmin for 10 days on the basis of conventional antiplatelet therapy. The National Institutes of Health Stroke Scale (NHISS) score and the modified Rankin (mRS) score at 3-month follow-up were evaluated before treatment and 1 week after treatment to understand the changes of neurological function and prognosis. At the same time, cranial CT/MRI, blood biochemistry, coagulation and other examinations before and after treatment were performed to exclude adverse events (including symptomatic intracranial hemorrhage and other organ hemorrhage). Results The NHISS scores of the AIS patients in the argatroban group and plasmin group were significantly decreased after 1 week of treatment compared with those before treatment (P<0.01); the mRS was significantly decreased after 3 months of follow-up (P<0.05). The total clinical effective rate in the argatroban group was significantly higher than that in the plasmin group after 1 week of treatment (P<0.05). After 1 week treatment of the two groups, the re-examination of cranial CT and biochemical test indicators showed that there were no adverse events (P>0.05). Conclusion Early application of argatroban and plasmin in AIS patients can improve neurological deficits, and the two groups do not increase the occurrence of adverse events, and the clinical efficacy of argatroban is better.

Objective To analyze the expression of miR-125b-5p in lung adenocarcinoma (LUAD), and predict its target genes and prognostic value by bioinformatics analysis. Methods Tissue and cell chips of cisplatin resistance-related LUAD in Gene Expression Omnibus (GEO) database were obtained, and differentially expressed miRNAs were screened by R software. The miRBase database was used to analyze conservativeness, and the dbDEMC3.0 database was used to evaluate the expression level. The target genes were predicted by TargetScan, miRDB and miRTarBase databases, and were analyzed for functional term enrichment with the DAVID database. Combined with the survival information of LUAD patients in the Cancer Genome Atlas (TCGA) database, prognostic analysis was performed. Quantitative Real-time PCR (qRT-PCR) detection technology was used to detect the expression level of miR-125b-5p in human normal bronchial epithelial cell line 16HBE, LUAD cell line A549, and cisplatin-resistance cell line A549/DDP. Results miR-125b-5p, closely related to cisplatin resistant of LUAD, was obtained by analysis of the chip data. The sequence of miR-125b-5p was highly conserved among species, and miR-125b-5p was significantly down-regulated in various tumors including LUAD. Fifty-four target genes of miR-125b-5p were predicted. The results of enrichment analysis showed that the target genes of miR-125b-5p were mainly involved in the regulation of gene expression, cellular macromolecule biosynthetic process, and mainly enriched on MicroRNAs in cancer, Protein processing in endoplasmic reticulum, and HIF-1 signaling pathway. Survival analysis indicated that miR-125b-5p was significantly associated with poor prognosis of patients with LUAD. qRT-PCR results showed that the expression level of miR-125b-5p in A549 was significantly lower than in 16HBE (P=0.008). Compared to parental cell, the expression level of miR-125b-5p was significantly down-regulated in A549/DDP cell (P=0.023). Conclusion miR-125b-5p was abnormally expressed in LUAD, and its target genes involved in multiple biological processes and signal pathways, which might be used as a new biomarker for prognosis in LUAD.